Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
179.88 +4.83 (+2.76%) 15:47 ET [NYSE]
179.86 x 1 180.02 x 160
Realtime by (Cboe BZX)
179.86 x 1 180.02 x 160
Realtime 177.81 +2.76 (+1.58%) 09:29 ET
Quote Overview for Mon, Apr 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
176.29
Day High
179.92
Open 177.44
Previous Close 175.05 175.05
Volume 4,636,471 4,636,471
Avg Vol 9,472,432 9,472,432
Stochastic %K 24.81% 24.81%
Weighted Alpha +2.87 +2.87
5-Day Change -7.09 (-3.80%) -7.09 (-3.80%)
52-Week Range 153.58 - 218.66 153.58 - 218.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 309,659,584
  • Shares Outstanding, K 1,768,978
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,130 M
  • EBITDA $ 17,516 M
  • 60-Month Beta 0.55
  • Price/Sales 5.47
  • Price/Cash Flow 11.67
  • Price/Book 91.51

Options Overview Details

View History
  • Implied Volatility 37.26% ( -8.24%)
  • Historical Volatility 35.35%
  • IV Percentile 97%
  • IV Rank 59.86%
  • IV High 51.27% on 04/08/25
  • IV Low 16.36% on 05/10/24
  • Put/Call Vol Ratio 0.84
  • Today's Volume 30,429
  • Volume Avg (30-Day) 32,839
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 421,144
  • Open Int (30-Day) 387,179

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.38
  • Number of Estimates 2
  • High Estimate 2.39
  • Low Estimate 2.36
  • Prior Year 2.31
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.39 +9.17%
on 04/09/25
Period Open: 211.77
215.50 -16.72%
on 03/17/25
-32.31 (-15.25%)
since 03/14/25
3-Month
164.39 +9.17%
on 04/09/25
Period Open: 175.55
218.66 -17.93%
on 03/10/25
+3.91 (+2.23%)
since 01/14/25
52-Week
153.58 +16.85%
on 05/30/24
Period Open: 162.28
218.66 -17.93%
on 03/10/25
+17.18 (+10.59%)
since 04/12/24

Most Recent Stories

More News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While AbbVie also markets products for aesthetics, neuroscience and eye care, Merck has...

NVO : 66.29 (+2.41%)
MRK : 79.36 (+0.23%)
LLY : 757.50 (+3.43%)
ABBV : 179.96 (+2.80%)
Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

XLV : 138.99 (+1.55%)
$SPX : 5,430.27 (+1.25%)
ABBV : 179.96 (+2.80%)
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

For Immediate ReleasesChicago, IL – April 14, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

AZN : 68.27 (+2.99%)
NVS : 109.61 (+1.94%)
ABBV : 179.96 (+2.80%)
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and AstraZeneca’s AZN blockbuster cancer drugs, Imfinzi and Daiichi-Sankyo partnered,...

AZN : 68.27 (+2.99%)
NVS : 109.61 (+1.94%)
ABBV : 179.96 (+2.80%)
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?

Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49Though the stock has seen ups and downs in the past year, the latest price decline is largely...

LLY : 757.50 (+3.43%)
ABBV : 179.96 (+2.80%)
PFE : 22.17 (+1.19%)
BNTX : 103.21 (+6.93%)
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs

The stock market was on a roller coaster on April 9 amid the ongoing global trade war triggered by a new series of tariffs by the U.S. government. Most of the pharma bigwigs ended the trading session in...

AZN : 68.27 (+2.99%)
NVO : 66.29 (+2.41%)
LLY : 757.50 (+3.43%)
ABBV : 179.96 (+2.80%)
3 Biopharmaceutical Stocks Bucking the Sell-Off

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

CORT : 67.65 (-1.41%)
DBVT : 7.78 (+6.28%)
SLRN : 2.19 (-1.79%)
ABBV : 179.96 (+2.80%)
ALMS : 5.25 (-18.98%)
The Last Time the Stock Market Started a Year This Badly Was 2022. Is Another Crash Coming?

As of Monday's close, the S&P 500 has fallen by about 15% this year (although the index regained about half of that after President Donald Trump put most of his tariff plan on pause). The index is coming...

XOM : 103.81 (+0.65%)
PG : 169.77 (+1.71%)
HDV : 113.60 (+1.59%)
ABBV : 179.96 (+2.80%)
Stocks Spike as Trump Announces 90-Day Tariff Pause

The S&P 500 Index ($SPX ) (SPY ) today is up +5.99%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +3.96%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +7.05%. June E-mini S&P futures (ESM25...

ALK : 45.32 (-0.96%)
GOOGL : 159.91 (+1.76%)
MPC : 125.62 (+1.77%)
AAPL : 205.45 (+3.68%)
JNJ : 154.50 (+1.83%)
AMGN : 294.68 (+3.04%)
PFE : 22.17 (+1.19%)
OXY : 38.08 (+1.09%)
TSLA : 255.22 (+1.15%)
FANG : 128.79 (-0.17%)
AMD : 95.18 (+1.91%)
SPY : 541.66 (+1.45%)
Stocks Supported by Strength in Megacap Technology and Airline Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25...

ALK : 45.32 (-0.96%)
GOOGL : 159.91 (+1.76%)
MPC : 125.62 (+1.77%)
AAPL : 205.45 (+3.68%)
ADI : 180.07 (+0.51%)
JNJ : 154.50 (+1.83%)
AMGN : 294.68 (+3.04%)
PFE : 22.17 (+1.19%)
OXY : 38.08 (+1.09%)
TSLA : 255.22 (+1.15%)
FANG : 128.79 (-0.17%)
AMD : 95.18 (+1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 185.88
2nd Resistance Point 181.42
1st Resistance Point 178.24
Last Price 179.84
1st Support Level 170.60
2nd Support Level 166.14
3rd Support Level 162.96

See More

52-Week High 218.66
Fibonacci 61.8% 193.80
Fibonacci 50% 186.12
Last Price 179.84
Fibonacci 38.2% 178.44
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar